580 related articles for article (PubMed ID: 33547249)
1. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
Struzyna LA; Watt ML
Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery through stem cell-based organoid models.
Ranga A; Gjorevski N; Lutolf MP
Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
[TBL] [Abstract][Full Text] [Related]
3. Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.
Costamagna G; Comi GP; Corti S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800815
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery in psychopharmacology: from 2D models to cerebral organoids
.
Rossetti AC; Koch P; Ladewig J
Dialogues Clin Neurosci; 2019; 21(2):203-224. PubMed ID: 31636494
[TBL] [Abstract][Full Text] [Related]
5. Application of porcine gastrointestinal organoid units as a potential in vitro tool for drug discovery and development.
Olayanju A; Jones L; Greco K; Goldring CE; Ansari T
J Appl Toxicol; 2019 Jan; 39(1):4-15. PubMed ID: 29893059
[TBL] [Abstract][Full Text] [Related]
6. Retinal Organoids: A Next-Generation Platform for High-Throughput Drug Discovery.
Zhao H; Yan F
Stem Cell Rev Rep; 2024 Feb; 20(2):495-508. PubMed ID: 38079086
[TBL] [Abstract][Full Text] [Related]
7. A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids.
Renner H; Grabos M; Becker KJ; Kagermeier TE; Wu J; Otto M; Peischard S; Zeuschner D; TsyTsyura Y; Disse P; Klingauf J; Leidel SA; Seebohm G; Schöler HR; Bruder JM
Elife; 2020 Nov; 9():. PubMed ID: 33138918
[TBL] [Abstract][Full Text] [Related]
8. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
Corti S; Faravelli I; Cardano M; Conti L
Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
[TBL] [Abstract][Full Text] [Related]
9. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.
Boehnke K; Iversen PW; Schumacher D; Lallena MJ; Haro R; Amat J; Haybaeck J; Liebs S; Lange M; Schäfer R; Regenbrecht CR; Reinhard C; Velasco JA
J Biomol Screen; 2016 Oct; 21(9):931-41. PubMed ID: 27233291
[TBL] [Abstract][Full Text] [Related]
10. Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease.
Vieira de Sá R; Cañizares Luna M; Pasterkamp RJ
Tissue Eng Part C Methods; 2021 Mar; 27(3):213-224. PubMed ID: 33446055
[TBL] [Abstract][Full Text] [Related]
11. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
[TBL] [Abstract][Full Text] [Related]
12. Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.
Hou S; Tiriac H; Sridharan BP; Scampavia L; Madoux F; Seldin J; Souza GR; Watson D; Tuveson D; Spicer TP
SLAS Discov; 2018 Jul; 23(6):574-584. PubMed ID: 29673279
[TBL] [Abstract][Full Text] [Related]
13. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
Burkhart RA; Baker LA; Tiriac H
Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
[TBL] [Abstract][Full Text] [Related]
14. Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening.
Eglen R; Reisine T
Assay Drug Dev Technol; 2011 Apr; 9(2):108-24. PubMed ID: 21186936
[TBL] [Abstract][Full Text] [Related]
15. Assay establishment and validation of a high-throughput organoid-based drug screening platform.
Li X; Fu G; Zhang L; Guan R; Tang P; Zhang J; Rao X; Chen S; Xu X; Zhou Y; Deng Y; Lv T; He X; Mo S; Mu P; Gao J; Hua G
Stem Cell Res Ther; 2022 May; 13(1):219. PubMed ID: 35619149
[TBL] [Abstract][Full Text] [Related]
16. High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing.
Jun HR; Kang HJ; Ju SH; Kim JE; Jeon SY; Ku B; Lee JJ; Kim M; Kim MJ; Choi JJ; Noh JJ; Kim HS; Lee JW; Lee JK; Lee DW
Biomaterials; 2023 May; 296():122087. PubMed ID: 36924663
[TBL] [Abstract][Full Text] [Related]
17. High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.
Shinozawa T; Kimura M; Cai Y; Saiki N; Yoneyama Y; Ouchi R; Koike H; Maezawa M; Zhang RR; Dunn A; Ferguson A; Togo S; Lewis K; Thompson WL; Asai A; Takebe T
Gastroenterology; 2021 Feb; 160(3):831-846.e10. PubMed ID: 33039464
[TBL] [Abstract][Full Text] [Related]
18. Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson's Disease for Drug Identification.
Kouroupi G; Antoniou N; Prodromidou K; Taoufik E; Matsas R
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993172
[TBL] [Abstract][Full Text] [Related]
19.
Romussi S; Giunti S; Andersen N; De Rosa MJ
Expert Opin Drug Discov; 2024 May; 19(5):565-585. PubMed ID: 38509691
[TBL] [Abstract][Full Text] [Related]
20. Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery.
Qian L; Tcw J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
